| Autor: |
Stephane Legriel, Fabrice Bruneel, Odile Spreux-Varoquaux, Aurelie Birenbaum, Marie Chadenat, François Mignon, Nathalie Abbosh, Matthieu Henry-Lagarrigue, Laure Revault D’Allonnes, Pierre Guezennec, Gilles Troche, Jean Bedos |
| Předmět: |
|
| Zdroj: |
Neurocritical Care; Oct2008, Vol. 9 Issue 2, p247-252, 6p |
| Abstrakt: |
Abstract Introduction Posterior reversible encephalopathy syndrome (PRES) is known to occur in association with several substances. However, lysergic acid amide (LSA) is not among the previously reported causes of PRES. Methods We report on a patient with PRES presenting as convulsive status epilepticus associated with hypertensive encephalopathy after LSA ingestion. Magnetic resonance imaging was performed and catecholamine metabolites assayed. Results The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsivant therapy. The clinical history, blood and urinary catecholamine levels, and response to treatment strongly suggest that PRES was induced by LSA. Conclusion LSA, a hallucinogenic agent chiefly used for recreational purposes, should be added to the list of causes of PRES. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink